Toll-like receptors: Sensing and reacting to diabetic injury in the kidney

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 746-754

  Lin, Miao ^a   Tang, Sydney C W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

diabetic nephropathy; fibrosis; inflammation; toll like receptor

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DISEASE COURSE; FIBROBLAST; HUMAN; KIDNEY CELL; KIDNEY FIBROSIS; LEUKOCYTE; MACROPHAGE; METABOLIC STRESS; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

DIABETIC NEPHROPATHY; FIBROSIS; INFLAMMATION; TOLL-LIKE RECEPTOR;

DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNITY, INNATE; KIDNEY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84897464330     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft446     Document Type: Review

References (137)

1. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442
2. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013; 124: 139-152
3. Lai KN, Leung JC, Tang SC. The renin-Angiotensin system. Contrib Nephrol 2011; 170: 135-144
4. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-2984
5. Kelly KJ, Dominguez JH. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 2010; 32: 469-475
6. Mezzano S, Aros C, Droguett A et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-2512
7. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
8. Tang SC, Leung JC, Chan LY et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-Activated receptor-gamma agonist. J Am Soc Nephrol 2006; 17: 1633-1643
9. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAGPKC-ERK pathway. Am J Kidney Dis 2001; 38(4 Suppl 1):S178-S181
10. Toyoda M, Suzuki D, Honma M et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 2004; 66: 1107-1114
11. Marrero MB, Banes-Berceli AK, Stern DM et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F762-F768
12. Chow F, Ozols E, Nikolic-Paterson DJ et al. Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128
13. Wu CC, Sytwu HK, Lu KC et al. Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res 2011; 2011: 514738
14. Chow FY, Nikolic-Paterson DJ, Atkins RC et al. Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrol Dial Transplant 2004; 19: 2987-2996
15. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-377
16. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-263
17. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010; 11: 373-384
18. Shirali AC, Goldstein DR. Tracking the toll of kidney disease. J Am Soc Nephrol 2008; 19: 1444-1450
19. Devaraj S, Dasu MR, Rockwood J et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: Further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-583
20. Devaraj S, Dasu MR, Park SH et al. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009; 52: 1665-1668
21. Dasu MR, Devaraj S, Park S et al. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010; 33: 861-868
22. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010; 22: 124-130
23. Kokkinopoulos I, Jordan WJ, Ritter MA. Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol Immunol 2005; 42: 957-968
24. Anders HJ, Banas B, Schlondorff D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854-867
25. Banas MC, Banas B, Hudkins KL et al. TLR4 Links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19: 704-713
26. Wolf G, Bohlender J, Bondeva T et al. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 2006; 17: 1585-1593
27. Kaur H, Chien A, Jialal I. Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: Relevance to diabetic nephropathy. Am J Physiol Renal Physiol 2012; 303: F1145-F1150
28. Chen J, John R, Richardson JA et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 2011; 79: 288-299
29. Takata S, Sawa Y, Uchiyama T et al. Expression of Toll-like receptor 4 in glomerular endothelial cells under diabetic conditions. Acta Histochem Cytochem 2013; 46: 35-42
30. Summers SA, van der Veen BS, O'Sullivan KM et al. Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis. Kidney Int 2010; 78: 1263-1274
31. Kruger B, Krick S, Dhillon N et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009; 106: 3390-3395
32. Wu H, Chen G, Wyburn KR et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-2859
33. Pulskens WP, Teske GJ, Butter LM et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One 2008; 3: E3596
34. Pulskens WP, Rampanelli E, Teske GJ et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 2010; 21: 1299-1308
35. Sorensen I, Susnik N, Inhester T et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 2011; 80: 1035-1044
36. Campbell MT, Hile KL, Zhang H et al. Toll-like receptor 4: A novel signaling pathway during renal fibrogenesis. J Surg Res 2011; 168: E61-e69
37. Correa-Costa M, Braga TT, Semedo P et al. Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS One 2011; 6: E29004
38. Zhang B, Ramesh G, Uematsu S et al. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008; 19: 923-932
39. Lim BJ, Hong SW, Jeong HJ. Renal tubular expression of Toll-like receptor 4 in cyclosporine nephrotoxicity. APMIS 2009; 117: 583-591
40. Kim J, Long KE, Tang K et al. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 2012; 82: 193-203
41. LinM, YiuWH, Wu HJ et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102
42. Li F, Yang N, Zhang L et al. Increased expression of toll-like receptor 2 in rat diabetic nephropathy. Am J Nephrol 2010; 32: 179-186
43. Leemans JC, Stokman G, Claessen N et al. Renal-Associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894-2903
44. Chen J, Hartono JR, John R et al. Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int 2011; 80: 504-515
45. Sallustio F, De Benedictis L, Castellano G et al. TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB J 2010; 24: 514-525
46. Sallustio F, Costantino V, Cox SN et al. Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney Int 2013; 83: 392-403
47. Meldrum KK, Zhang H, Hile KL et al. Profibrotic effect of interleukin-18 in HK-2 cells is dependent on stimulation of the Toll-like receptor 4 (TLR4) promoter and increased TLR4 expression. J Biol Chem 2012; 287: 40391-40399
48. Hanke ML, Angle A, Kielian T. MyD88-dependent signaling influences fibrosis and alternative macrophage activation during Staphylococcus aureus biofilm infection. PLoS One 2012; 7: E42476
49. Leemans JC, Butter LM, Pulskens WP et al. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One 2009; 4: E5704
50. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-305
51. Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108
52. Koc M, Toprak A, Arikan H et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: Relation with inflammation. Nephrol Dial Transplant 2011; 26: 955-963
53. Ohashi K, Burkart V, Flohe S et al. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-561
54. Vabulas RM, Ahmad-Nejad P, Ghose S et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107-15112
55. Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002; 277: 20847-20853
56. Vogl T, Tenbrock K, Ludwig S et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049
57. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-2894
58. Guillot L, Balloy V, McCormack FX et al. Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168: 5989-5992
59. Johnson GB, Brunn GJ, Kodaira Y et al. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168: 5233-5239
60. Taylor KR, Trowbridge JM, Rudisill JA et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279: 17079-17084
61. Erridge C. Endogenous ligands of TLR2 and TLR4: Agonists or assistants? J Leukoc Biol 2010; 87: 989-999
62. de Graaf R, Kloppenburg G, Kitslaar PJ et al. Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect 2006; 8: 1859-1865
63. Klune JR, Dhupar R, Cardinal J et al. HMGB1: Endogenous danger signaling. Mol Med 2008; 14: 476-484
64. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255
65. Volz HC, Seidel C, Laohachewin D et al. HMGB1: The missing link between diabetes mellitus and heart failure. Basic Res Cardiol 2010; 105: 805-820
66. Kim J, Sohn E, Kim CS et al. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 2011; 33: 524-529
67. Kuwabara T, Mori K, Mukoyama M et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia 2012; 55: 2256-2266
68. Gariboldi S, Palazzo M, Zanobbio L et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol 2008; 181: 2103-2110
69. Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029
70. Biragyn A, Coscia M, Nagashima K et al. Murine beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-kappaB-dependent atypical death of APCs via activation of TNFR2. J Leukoc Biol 2008; 83: 998-1008
71. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229-10233
72. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-2233
73. Babelova A, Moreth K, Tsalastra-Greul Wet al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 2009; 284: 24035-24048
74. Midwood K, Sacre S, Piccinini AM et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-780
75. Kim S, Takahashi H, LinWWet al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-106
76. Bae YS, Lee JH, Choi SH et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Tolllike receptor 4-And spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009; 104: 210-218, 221p following 218
77. Miller YI, Viriyakosol S, Binder CJ et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278: 1561-1568
78. Miller YI, Viriyakosol S, Worrall DS et al. Toll-like receptor 4-dependent and-independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 1213-1219
79. Holvoet P, Davey PC, De Keyzer D et al. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: Studies in hypercholesterolemic swine and THP-1 cells. Arterioscler Thromb Vasc Biol 2006; 26: 1558-1565
80. Cheng A, Dong Y, Zhu F et al. AGE-LDL activates Toll like receptor 4 pathway and promotes inflammatory cytokines production in renal tubular epithelial cells. Int J Biol Sci 2013; 9: 94-107
81. West XZ, Malinin NL, Merkulova AA et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010; 467: 972-976
82. Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-35292
83. Cha JJ, Hyun YY, Lee MH et al. Renal protective effects of Toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology 2013; 154: 2144-2155
84. Kim F, Pham M, Luttrell I et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007; 100: 1589-1596
85. Pal D, Dasgupta S, Kundu R et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285
86. Bondeva T, Roger T, Wolf G. Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: Dependency on AP1 and PU.1 transcriptional sites. Am J Nephrol 2007; 27: 308-314
87. Tukel C, Wilson RP, Nishimori JH et al. Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. Cell Host Microbe 2009; 6: 45-53
88. Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947
89. He RL, Zhou J, Hanson CZ et al. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113: 429-437
90. Dasu MR, Devaraj S, Zhao L et al. High glucose induces toll-like receptor expression in human monocytes: Mechanism of activation. Diabetes 2008; 57: 3090-3098
91. Reyna SM, Ghosh S, Tantiwong P et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008; 57: 2595-2602
92. Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab 2011; 300: E145-E154
93. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-1998
94. Poggi M, Bastelica D, Gual P et al. C3h/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50: 1267-1276
95. Speer T, Rohrer L, Blyszczuk P et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013; 38: 754-768
96. Rabadi MM, Kuo MC, Ghaly T et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Renal Physiol 2012; 302: F730-F741
97. Lv J, Jia R, Yang D et al. Candesartan attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 2009; 380: 81-86
98. Liu KH, Zhou QL, Ao X et al. Effect of spironolactone on the expression of Toll-like receptor 4 in renal tubular epithelia cells exposed to high glucose. Zhongguo Dang Dai Er Ke Za Zhi 2010; 12: 280-283
99. Powers KA, Szaszi K, Khadaroo RG et al. Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages. J Exp Med 2006; 203: 1951-1961
100. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-550
101. Lin M, Yiu WH, Li RX et al. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 2013; 83: 887-900
102. Motojima M, Matsusaka T, Kon V et al. Fibrinogen that appears in Bowman's space of proteinuric kidneys in vivo activates podocyte Tolllike receptors 2 and 4 in vitro. Nephron Exp Nephrol 2010; 114: E39-e47
103. Devaraj S, Tobias P, Kasinath BS et al. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 2011; 31: 1796-1804
104. Mudaliar H, Pollock CA, Komala MG et al. The role of Toll-Like receptor proteins (Tlr) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol 2013; 305: F143-F154
105. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract 2010; 2010: 212563-212574
106. Kim DH, Lee JC, Kim S et al. Inhibition of autoimmune diabetes by TLR2 tolerance. J Immunol 2011; 187: 5211-5220
107. Methe H, Kim JO, Kofler S et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005; 25: 1439-1445
108. Niessner A, Steiner S, Speidl WS et al. Simvastatin suppresses endotoxininduced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189: 408-413
109. Dasu MR, Park S, Devaraj S et al. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009; 150: 3457-3464
110. Sochorova K, Budinsky V, Rozkova D et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133: 69-77
111. Ta NN, Li Y, Schuyler CA et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010; 213: 429-435
112. Ta NN, Schuyler CA, Li Y et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58: 157-166
113. Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013; 8: E54442
114. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: Emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307
115. Mullarkey M, Rose JR, Bristol J et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-1102
116. Shirey KA, Lai W, Scott AJ et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497: 498-502
117. Shimamoto A, Chong AJ, Yada M et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114(1 Suppl):I270-I274
118. Liu M, Gu M, Xu D et al. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 2010; 42: 1539-1544
119. Abe T, Hirasaka K, Kagawa S et al. Cbl-b is a critical regulator of macrophage activation associated with obesity-induced insulin resistance in mice. Diabetes 2013; 62: 1957-1969
120. Opal SM, Laterre PF, Francois B et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 2013; 309: 1154-1162
121. Fort MM, Mozaffarian A, Stover AG et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005; 174: 6416-6423
122. Zanotti G, Casiraghi M, Abano JB et al. Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema. Am J Physiol Lung Cell Mol Physiol 2009; 297: L52-L63
123. Rice TW, Wheeler AP, Bernard GR et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38: 1685-1694
124. Hutchinson MR, Lewis SS, Coats BD et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009; 23: 240-250
125. Hoshino T, Ikeda T. Inhibitory effect of ibudilast on urinary albumin excretion in type 2 diabetes mellitus with microalbuminuria. Nephron 2002; 90: 154-157
126. Chang YC, Kao WC, Wang WY et al. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-Associated immune responses. FASEB J 2009; 23: 3078-3088
127. Yang H, Hreggvidsdottir HS, Palmblad K et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-11947
128. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger? Science 2010; 327: 296-300
129. Du P, Fan B, Han H et al. NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy. Kidney Int 2013; 84: 265-276
130. Chen K, Zhang J, Zhang W et al. ATP-P2X4 signaling mediates NLRP3 inflammasome activation: A novel pathway of diabetic nephropathy. Int J Biochem Cell Biol 2013; 45: 932-943
131. Wang C, Pan Y, Zhang QY et al. Quercetin and allopurinol ameliorate kidney injury in STZ-Treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One 2012; 7: E38285
132. Kelly DJ, Chanty A, Gow RM et al. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16: 1654-1660
133. Sayyed SG, Ryu M, Kulkarni OP et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 2011; 80: 68-78
134. Kang YS, Lee MH, Song HK et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010; 78: 883-894
135. Ninichuk V, Khandoga AG, Segerer S et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007; 170: 1267-1276
136. Zheng H, Whitman SA, Wu W et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011; 60: 3055-3066
137. Fernandez Fernandez B, Elewa U, Sanchez-Nino MD et al. 2012 update on diabetic kidney disease: The expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med 2012; 103: 219-234